Business Description
I-MAB
ISIN : US44975P1030
Share Class Description:
STU:0VY: ADRDescription
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 52.41 | |||||
| Equity-to-Asset | 0.93 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -4.87 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -76.1 | |||||
| 3-Year Book Growth Rate | -37 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | -33.52 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 60.08 | |||||
| 9-Day RSI | 62.15 | |||||
| 14-Day RSI | 61.61 | |||||
| 6-1 Month Momentum % | -42.26 | |||||
| 12-1 Month Momentum % | -19.83 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 16.5 | |||||
| Quick Ratio | 16.5 | |||||
| Cash Ratio | 14.85 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4 | |||||
| Shareholder Yield % | -0.55 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 222.66 | |||||
| Operating Margin % | -4870.71 | |||||
| Net Margin % | -2587.99 | |||||
| FCF Margin % | -5175.65 | |||||
| ROE % | -34.12 | |||||
| ROA % | -25.17 | |||||
| ROIC % | -343.71 | |||||
| 3-Year ROIIC % | 185.75 | |||||
| ROC (Joel Greenblatt) % | -1588.97 | |||||
| ROCE % | -66.49 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 34.42 | |||||
| PB Ratio | 0.49 | |||||
| Price-to-Tangible-Book | 0.45 | |||||
| EV-to-EBIT | 0.46 | |||||
| EV-to-Forward-EBIT | -0.01 | |||||
| EV-to-EBITDA | 0.48 | |||||
| EV-to-Forward-EBITDA | -0.01 | |||||
| EV-to-Revenue | -26.85 | |||||
| EV-to-Forward-Revenue | 0.17 | |||||
| EV-to-FCF | 0.48 | |||||
| Price-to-Net-Current-Asset-Value | 0.5 | |||||
| Price-to-Net-Cash | 0.56 | |||||
| Earnings Yield (Greenblatt) % | 219.18 | |||||
| FCF Yield % | -173.1 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers